Literature DB >> 12676356

Conjugated linoleic acid exhibits stimulatory and inhibitory effects on prostanoid production in human endothelial cells and platelets.

Armida P Torres-Duarte1, Jack Y Vanderhoek.   

Abstract

In addition to their reported antitumorigenic properties, various conjugated linoleic acid (CLA) isomers have also been shown to decrease prostanoid synthesis as a result of inhibiting the cyclooxygenase (COX) enzyme. We have previously reported that several CLA isomers inhibited both platelet aggregation and formation of thromboxane A(2) (TXA(2)), a proaggregatory and vasoconstrictive agent. Since the interaction between platelets and vascular endothelial cells is essential to maintaining vascular homeostasis, we decided to investigate the effects of various CLA isomers on the production of endothelial prostacyclin (PGI(2)), a potent vasodilator and inhibitor of platelet function. Using interleukin 1-beta (IL1-beta)-stimulated human umbilical vein endothelial cells (HUVECs), we initially established that HUVECs of passage #2 should be used since these cells were most responsive to thrombin-induced conversion of endogenous arachidonic acid to PGI(2), as monitored by the formation of its stable, inactive metabolite, 6-ketoPGF(1alpha). In the first part of the study, the effects of CLA isomers in the free fatty acid form were tested. The 10(E), 12(Z)- and 9(Z), 11(E)-CLA isomers inhibited thrombin-induced 6-ketoPGF(1alpha) formation with I(50)'s of 2.6 and 5.5 microM, whereas the 9(Z), 11(Z)- and 9(E), 11(E)-CLA were ineffective at concentrations up to 60 microM. The inhibitory effect of the 10(E), 12(Z)-CLA was irreversible. Next, the effects of CLA incorporation into HUVECs on PGI(2) generation was determined. An average 8-fold stimulation of 6-ketoPGF(1alpha) formation was obtained with quiescent IL1-beta-exposed HUVECs pretreated for 18 h with 25 microM 9(Z), 11(Z)-CLA, whereas cells preincubated with the 10(E), 12(Z) isomer enhanced this eicosanoid 3-fold. Such IL1-beta-treated HUVECs prelabeled with 25 microM 9(Z), 11(Z)-CLA became refractory to thrombin stimulation, as measured by 6-ketoPGF(1alpha) production, whereas a small, statistically insignificant, inhibition was observed upon thrombin treatment of HUVECs prelabeled with the 10(E), 12(Z) isomer. Qualitative similar results were obtained with resting or thrombin-stimulated platelets containing these esterified CLA isomers indicating that these effects occur with cells that contain either the COX-1 or COX-2 isozymes. The results of this in vitro study indicate that the effects of CLA on cellular prostanoid formation in endothelial cells and platelets can be either inhibitory or stimulatory, and this seems to depend not only on the specific CLA isomer and whether or not the CLA is in the free fatty acid form or esterified into cellular lipids, but also whether cells are in the resting or stimulated state. These findings suggest that in vivo, CLA might have multiple, complex effects on vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676356     DOI: 10.1016/s0167-4889(03)00005-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Inhibition of phospholipase A(2) activity by conjugated linoleic acids in human macrophages.

Authors:  Ewa Stachowska; Violetta Dziedziejko; Krzysztof Safranow; Izabela Gutowska; Grazyna Adler; Andrzej Ciechanowicz; Bogusław Machaliński; Dariusz Chlubek
Journal:  Eur J Nutr       Date:  2006-12-11       Impact factor: 5.614

2.  9-trans, 11-trans-CLA: antiproliferative and proapoptotic effects on bovine endothelial cells.

Authors:  Kuan-Lin Lai; Armida P Torres-Duarte; Jack Y Vanderhoek
Journal:  Lipids       Date:  2005-11       Impact factor: 1.880

3.  Conjugated linoleic acids and CLA-containing phospholipids inhibit NO formation in aortic endothelial cells.

Authors:  Kimberly J Jenko; Jack Y Vanderhoek
Journal:  Lipids       Date:  2008-03-12       Impact factor: 1.880

4.  Conjugated linoleic acid isomers inhibit platelet-derived growth factor-induced NF-kappaB transactivation and collagen formation in human vascular smooth muscle cells.

Authors:  Robert Ringseis; Susan Gahler; Klaus Eder
Journal:  Eur J Nutr       Date:  2008-02-09       Impact factor: 5.614

Review 5.  Lipophilic compound-mediated gene expression and implication for intervention in reactive oxygen species (ROS)-related diseases: mini-review.

Authors:  Yukiko K Nakamura; Stanley T Omaye
Journal:  Nutrients       Date:  2010-07-07       Impact factor: 5.717

6.  Individual CLA Isomers, c9t11 and t10c12, Prevent Excess Liver Glycogen Storage and Inhibit Lipogenic Genes Expression Induced by High-Fructose Diet in Rats.

Authors:  Edyta Maslak; Elzbieta Buczek; Antoni Szumny; Wojciech Szczepnski; Magdalena Franczyk-Zarow; Aneta Kopec; Stefan Chlopicki; Teresa Leszczynska; Renata B Kostogrys
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

7.  Fabrication of Polycaprolactone/Polyurethane Loading Conjugated Linoleic Acid and Its Antiplatelet Adhesion.

Authors:  Ho Hieu Minh; Nguyen Thi Hiep; Nguyen Dai Hai; Vo Van Toi
Journal:  Int J Biomater       Date:  2017-05-16

8.  Influence of conjugated linoleic acid on the porcine immune response and morbidity: a randomized controlled trial.

Authors:  Tomaz Malovrh; Lidija Kompan; Polona Juntes; Branka Wraber; Alenka Spindler-Vesel; Drago Kompan
Journal:  Lipids Health Dis       Date:  2009-06-22       Impact factor: 3.876

9.  Conjugated linoleic acids can change phagocytosis of human monocytes/macrophages by reduction in Cox-2 expression.

Authors:  Ewa Stachowska; Magdalena Baśkiewicz-Masiuk; Violetta Dziedziejko; Grazyna Adler; Joanna Bober; Bogusław Machaliński; Dariusz Chlubek
Journal:  Lipids       Date:  2007-06-15       Impact factor: 1.646

10.  Conjugated linoleic acid modulation of risk factors associated with atherosclerosis.

Authors:  Yukiko K Nakamura; Nichole Flintoff-Dye; Stanley T Omaye
Journal:  Nutr Metab (Lond)       Date:  2008-08-21       Impact factor: 4.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.